DRL-Header DRL-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Vilobelimab

            Therapeutic Area: Dermatology Product Name: IFX-1

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2021


            The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG. Target enrollment of 18 patients reached across three different dose groups.